Wall Street Zen Downgrades Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) to Hold

Key Points

• Wall Street Zen downgraded Fresenius Medical Care AG & Co. KGaA from Buy to Hold, adding to a broader wave of cautious analyst sentiment on the stock.
• Several other firms have recently cut ratings as well, and the stock now has a consensus “Reduce” rating with an average price target of $28.00.
• The company missed quarterly expectations, reporting EPS of $0.53 versus $0.59 expected, while revenue came in slightly below estimates at $5.34 billion.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

A number of other brokerages have also issued reports on FMS. The Goldman Sachs Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a research report on Tuesday, January 20th. Erste Group Bank lowered shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 5th. Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday. Citigroup restated a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, April 24th. Finally, Jefferies Financial Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a "moderate sell" rating to a "strong sell" rating in a research report on Tuesday, February 24th. Six analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Reduce" and an average price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS opened at $22.02 on Friday. The firm has a 50-day moving average price of $22.68 and a 200 day moving average price of $23.43. The firm has a market capitalization of $12.30 billion, a PE ratio of 11.59, a P/E/G ratio of 3.71 and a beta of 0.81. The company has a quick ratio of 0.92, a current ratio of 1.20 and a debt-to-equity ratio of 0.40. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $20.02 and a 52-week high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $0.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.59 by ($0.06). The company had revenue of $5.34 billion during the quarter, compared to the consensus estimate of $5.41 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.88% and a return on equity of 8.90%. On average, sell-side analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Large investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company's stock valued at $36,000 after buying an additional 1,103 shares in the last quarter. Arax Advisory Partners lifted its stake in Fresenius Medical Care AG & Co. KGaA by 121.6% during the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company's stock valued at $38,000 after buying an additional 885 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in Fresenius Medical Care AG & Co. KGaA during the fourth quarter valued at about $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Fresenius Medical Care AG & Co. KGaA during the fourth quarter valued at about $58,000. Finally, Group One Trading LLC purchased a new stake in Fresenius Medical Care AG & Co. KGaA during the third quarter valued at about $74,000. Institutional investors own 8.37% of the company's stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world's largest integrated provider of products and services for individuals with renal diseases. The company's primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.